Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. Viewhere

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksChemring Regulatory News (CHG)

Share Price Information for Chemring (CHG)

Share Price is delayed by 15 minutes
Get Live Data
546.00    7.00 (1.30%)
Bid:
546.00
Ask:
547.00
Spread: 1.00 (0.183%)
Market Cap: £1.48b
CHG Live PriceLast checked at - London Stock Exchange

Intraday Chemring Share Chart

Trading Update

11 Oct 2013 07:00

RNS Number : 2645Q
Chemring Group PLC
11 October 2013
 



FOR IMMEDIATE RELEASE 11 OCTOBER 2013

 

CHEMRING GROUP PLC

 TRADING UPDATE

 

Chemring Group PLC ("Chemring") announces that its UK subsidiary, Chemring Countermeasures Ltd, has been awarded a significant countermeasures contract from a Middle Eastern customer. Revenue and profits associated with this contract will be recognised in the current financial year, as previously anticipated.

 

The US Government shut down that came into effect on 1 October has resulted in the closure of a large number of Government departments and associated activities. This included the Defense Contract Management Agency ("DCMA"), the Government agency with responsibility for inspecting and approving products for delivery to the US Department of Defense ("US DoD"). While the majority of the DCMA's civilian staff have now returned to work, other Government departments remain closed and this continues to affect Chemring's North American business. The full impact of the US Government shut down is not yet known but it will impact the October order intake and deliveries to the US DoD in the remaining few weeks of the financial year.

 

Since the publication of the third quarter Interim Management Statement in August, quality and production issues, particularly at Kilgore, have continued, resulting in reduced revenue for this financial year. In addition, the UK£:US$ exchange rate has moved adversely, reducing the sterling value of profits generated in the US.

 

The Board's current view is that these factors will impact this financial year's operating profit by approximately £8 million.

 

Recent tensions in the Middle East have constrained the availability of shipping to the region and this will have a short term impact on cash receipts for certain munitions contracts until the first quarter of FY14. However, we continue to closely manage cash and working capital.

 

FY14 Outlook

 

At the interim results presentation in June, Chemring announced that it was initiating a comprehensive planning process which would give a better understanding of both the markets in which we operate and our business strategy for the next three years. This is being prepared in conjunction with a detailed budgeting exercise for FY14. Early indications, given the continuing difficult market conditions, are that FY14 performance is likely to be less than the anticipated current year outturn. We will outline the initial findings of this process in a post close trading statement, which is expected to be released in November 2013.

 

-ENDS-

 

For further information:

 

Mark Papworth Group Chief Executive, Chemring Group PLC 01489 881880

Steve Bowers Group Finance Director, Chemring Group PLC 01489 881880

Rupert Pittman Group Director of Communications and

Investor Relations, Chemring Group PLC 01489 881880

 

Andrew Jaques MHP Communications 0203 128 8100

John Olsen

James White

 

 

Cautionary statement

 

This announcement is based on unaudited management accounts and contains forward-looking statements that are based on current expectations or beliefs, as well as assumptions about future events. These forward-looking statements can be identified by the fact that they do not relate only to historical or current facts. Forward-looking statements often use words such as anticipate, target, expect, estimate, intend, plan, goal, believe, will, may, should, would, could, is confident, or other words of similar meaning. Undue reliance should not be placed on any such statements because they speak only as at the date of this document and, by their very nature, they are subject to known and unknown risks and uncertainties and can be affected by other factors that could cause actual results, and Chemring's plans and objectives, to differ materially from those expressed or implied in the forward-looking statements.

 

There are a number of factors which could cause actual results to differ materially from those expressed or implied in forward-looking statements. Among the factors that could cause actual results to differ materially from those described in the forward-looking statements are; increased competition, the loss of or damage to one or more key customer relationships, changes to customer ordering patterns, delays in obtaining customer approvals for engineering or price level changes, the failure of one or more key suppliers, the outcome of business or industry restructuring, the outcome of any litigation, changes in economic conditions, currency fluctuations, changes in interest and tax rates, changes in raw material or energy market prices, changes in laws, regulations or regulatory policies, developments in legal or public policy doctrines, technological developments, the failure to retain key management, or the key timing and success of future acquisition opportunities or major investment projects.

 

Chemring undertakes no obligation to revise or update any forward-looking statement contained within this announcement, regardless of whether those statements are affected as a result of new information, future events or otherwise, save as required by law and regulations.

 

 

Notes to Editors

 

• Chemring is a manufacturing business with facilities in eight countries, selling high technology electronics and energetic products to over sixty countries worldwide.

 

• The Company has a diverse portfolio of products protecting military people and platforms against a constantly changing threat.

 

• Operating in niche markets with short product development timescales, Chemring has the agility to rapidly react to urgent customer needs.

 

• Strong R&D investment for new products and improvements in technology continually allows Chemring to expand its addressable markets.

 

www.chemring.co.uk

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTNKKDDDBDBDKD
Date   Source Headline
15th Dec 20212:00 pmRNSDirector/PDMR Shareholding
15th Dec 20212:00 pmRNSDirector/PDMR Shareholding
15th Dec 20212:00 pmRNSDirector/PDMR Shareholding
15th Dec 20212:00 pmRNSDirector/PDMR Shareholding
15th Dec 20212:00 pmRNSDirector/PDMR Shareholding
14th Dec 20214:36 pmRNSPrice Monitoring Extension
14th Dec 20217:00 amRNSResults for the year ended 31 October 2021
1st Dec 202110:04 amRNSTotal Voting Rights
2nd Nov 20217:00 amRNSTrading Update and Contract Awards
1st Nov 20213:37 pmRNSTotal Voting Rights
8th Oct 20217:00 amRNSStatement re CFC Finance Company Exemption
1st Oct 20219:34 amRNSTotal Voting Rights
28th Sep 20217:00 amRNSContract Awards
14th Sep 20217:00 amRNSScheduled Trading Update
1st Sep 202110:11 amRNSTotal Voting Rights
2nd Aug 202110:36 amRNSTotal Voting Rights
20th Jul 20212:59 pmRNSDirector/PDMR Shareholding
16th Jul 20219:59 amRNSDirector/PDMR Shareholding
1st Jul 202110:21 amRNSTotal Voting Rights
18th Jun 20211:25 pmRNSBlock listing Interim Review
3rd Jun 20217:00 amRNSAcquisition
3rd Jun 20217:00 amRNSInterim Results
1st Jun 202111:51 amRNSTotal Voting Rights
12th May 20214:18 pmRNSHolding(s) in Company
7th May 20213:59 pmRNSHolding(s) in Company
4th May 202110:38 amRNSTotal Voting Rights
13th Apr 20211:35 pmRNSDirector/PDMR Shareholding
8th Apr 202112:02 pmRNSDirector/PDMR Shareholding
1st Apr 20217:00 amRNSTotal Voting Rights
12th Mar 20217:00 amRNSHolding(s) in Company
5th Mar 20213:05 pmRNSDoc re. Ordinary & Special Resolutions
4th Mar 20211:42 pmRNSResult of AGM
4th Mar 20217:00 amRNSAGM Statement
1st Mar 20213:30 pmRNSTotal Voting Rights
18th Feb 20217:00 amRNSHolding(s) in Company
1st Feb 202112:09 pmRNSTotal Voting Rights
29th Jan 20217:00 amRNSHolding(s) in Company
25th Jan 20213:55 pmRNSNotice of AGM
19th Jan 20213:52 pmRNSDirector/PDMR Shareholding
19th Jan 20213:47 pmRNSDirector/PDMR Shareholding
19th Jan 20213:43 pmRNSDirector/PDMR Shareholding
19th Jan 20213:42 pmRNSDirector/PDMR Shareholding
4th Jan 202111:01 amRNSTotal Voting Rights
23rd Dec 202010:07 amRNSHolding(s) in Company
22nd Dec 20201:46 pmRNSCorrection re. Additional Listing
22nd Dec 20201:08 pmRNSAdditional Listing
22nd Dec 20209:39 amRNSHolding(s) in Company
18th Dec 202010:25 amRNSBlock listing Interim Review
17th Dec 20207:00 amRNSDirector/PDMR Shareholding
17th Dec 20207:00 amRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.